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Menopausal hot flushes after breast cancer
The study aimed to improve understanding of the natural history and impact of hot flushes after breast cancer.
Data were collected from women participating in an RCT of relaxation to reduce the incidence of flushes from
breast cancer follow-up clinics from two hospitals in South-East England. Repondents were 150 women
experiencing hot flushes following completion of primary treatment for breast cancer. This study utilized a
flush diary, the Hot Flushes and Night Sweats Questionnaire (HFNSQ), Functional Assessment of Cancer
Therapy with Endocrine Subscale (FACT-ES) and Spielberger State/Trait Anxiety Index (STAI) as the main
outcome measures. The study found that in this sample, 51 (34%) women experienced flushes more than five
years after diagnosis and 75 (50%) more than 5 years after menopause. Sleep disruption occurred in 90 women
(72% of those that returned diaries), affecting half of the nights they recorded. The mean problem rating on the
HFNSQ was 4.85 out of 10. A peak incidence of flushes was apparent around 10 a.m. in women taking
tamoxifen. It was concluded that hot flushes after breast cancer may be long-lasting and cause sleeping
difficulties for many women. Tamoxifen may affect the diurnal pattern of flushes. After breast cancer, the
duration of flushes, potential distress and disruption to women’s lives should not be underestimated and
appropriate interventions should be offered.
Keywords: breast cancer, menopause, hot flushes/flashes, tamoxifen, chemotherapy.
INTRODUCTION
Due to the role of oestrogen in promoting breast cancer
growth (Mokbel 2001), many treatments for breast cancer
suppress oestrogen levels, resulting in menopausal prob-
lems, and, in particular, hot flushes. As a result, hot flush
treatments, which raise oestrogen levels, including
hormone replacement therapy (HRT), are contraindicated
in women who have had breast cancer (Xydakis et al.
2006). It is well documented that up to 70% women expe-
rience disabling hot flushes after treatment for breast
cancer (McPhail & Smith 2000; Harris et al. 2002;
Carpenter & Andrykowski 1999). While the incidence of
flushes may be as much as 52% in peri-menopausal
women without breast cancer (Dennerstein et al. 2000), in
women with breast cancer flushes are not only more
likely, but they are exacerbated by a lack of safe and
effective management strategies (Harris et al. 2002).
Faced with this problem, women need to have an under-
standing of the course and causes of flushes in order to
make informed choices about treatment options. Cur-
rently, little is known about the long-term course of
recovery from treatment for primary breast cancer, and
advice on recovery is not based on scientific data (Stanton
et al. 2005). Information about the course of flushes fol-
lowing breast cancer treatment is also lacking. Women
cannot be told how long flushes will last, when and
whether the severity will subside, what treatments they
should take and for how long treatment should be taken.
There are some non-hormonal treatments available, such
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as venlafaxine (Barton et al. 2002; Evans et al. 2005) and
paroxetine (Stearns et al. 2003), which are reported to be
successful in reducing flushes. However, there may be
unpleasant side effects (van Gool et al. 2005), and many
women prefer not to take drugs, but to manage meno-
pausal flushes by self-help strategies (Shen et al. 2002).
Better information about this phenomenon may improve
coping and inform the development of techniques to
facilitate women’s coping with this difficult symptom.
In this paper, we present data on hot flushes from a
study of 150 women with breast cancer participating in a
randomized controlled trial (RCT) of relaxation training to
reduce the incidence of hot flushes. The results of the
RCT are presented elsewhere (Fenlon 2007). This paper
reports information gathered from these women about the
course, nature and impact of hot flushes they were
experiencing.
PATIENTS
Participants in the study were recruited from breast
cancer follow-up clinics from two hospitals in South-East
England. Women were invited to participate if they were
post-menopausal, diagnosed with non-metastatic breast
cancer and suffering from menopausal hot flushes. Post-
menopausal was defined as 6 months without menstrua-
tion. This criterion led to the inclusion of some women
for whom menstruation returned at a later date, but
was chosen so that women who were suffering from
chemotherapy-induced menopause would not be excluded
from the study. The women were also required to be able
to complete written records in English. Women using
HRT or other hormone therapies other than tamoxifen
were excluded. Those taking remedies or prescription
medicines likely to have an impact on hot flushes, such as
acupuncture (Cohen et al. 2003), venlafaxine or progester-
ones were also excluded. Ethical approval was given by the
local hospital ethics committee and written consent was
obtained from participants.
During a 1 month audit of recruitment, it was found
that 68% women approached were experiencing hot
flushes. Of these, 61% chose not to enter the study, as
they either did not consider their flushes severe enough to
warrant involvement in a clinical trial (37%), or flushes
were severe enough for the women to choose active treat-
ment over trial entry (24%). One hundred and fifty women
were recruited into the study, and demographic and treat-
ment details are given for these women. However, 25
withdrew before returning baseline data and so data on
flushing is described for 125 women. A further 21 with-
drew before completing data at 1 month (11 in treatment
group and 10 in control group), and a further seven before
the third month (four in the treatment group and three in
control). Reasons for withdrawal from the study were
varied, and ranged from family reasons, holidays, illness
and being too busy to not wanting to be reminded of
having had cancer.
METHODS
In the main study, from which data reported here were
taken, women attending the clinics were asked if they
were experiencing hot flushes and whether they would be
interested in taking part in a trial to see if relaxation
training could reduce flushes. Those recruited into the
study were asked to complete baseline measures and were
then randomly allocated to receive relaxation training or
to be in a control group.
Measures
Demographic and medical data were gathered from the
participants during the consent process. The incidence of
flushes was measured using a diary, kept by the women, of
every flush as it occurred over the period of 1 week. These
1-week diaries were completed at baseline, 1 month and
3 months. Diaries have been recommended for use in hot
flush research by a number of researchers (Sloan et al.
2001; Miller & Li 2004). The women also gave a measure
of the severity of each flush using pre-defined categories
based on work by Finck et al. (1998), who defined hot
flushes using interviews gathered from women with
breast cancer. There was also a separate question which
asked women if their sleep had been disturbed and to give
an estimate of how much sleep they had lost.
The distress caused by flushing was measured using the
Hot Flushes and Night Sweats Questionnaire (HFNSQ)
(Hunter & Liao 1995). Women scored from 0 to 10, where
0 was no problem and 10 was very much a problem, on
three problem-rating scales: the extent to which the symp-
toms are distressing, interfere with life, and are a problem.
We also collected data on quality of life using the Func-
tional Assessment of Cancer Therapy with the endocrine
subscale (FACT-ES) (Brady et al. 1997; Fallowfield et al.
1999), and anxiety, which was measured using the Spiel-
berger State/Trait Anxiety Index (STAI) (Spielberger 1983).
All measures were completed at baseline, and at 1 and
3 months after relaxation training. Data presented here
were collected at baseline unless otherwise specified.
Analysis
Data relating to demographics and treatments were ana-
lyzed using descriptive statistics. Summary statistics were
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provided on the number and severity of hot flushes as
described in the diaries. There were four domains of sever-
ity and each was graded 0–4. This gave a maximum pos-
sible score of 16 per flush and a minimum of one. The
median severity per flush was used in calculations. Non-
parametric statistics were used for analysis of flushes as
the distributions were skewed. Spearman correlations
were used to test whether there were any associations
between flushes and age, state and trait anxiety, marital
status, time since diagnosis, and time since last menstrua-
tion. The Mann–Whitney U-test was used to explore
whether there were differences in the number or severity
of flushing due to previous treatment. Change in the
number and severity of hot flushes over time was tested
using the Wilcoxon test for paired data. In order to allow
for multiple testing, the significance level was set at
0.01.The diurnal rhythm of hot flushes was observed by
plotting a simple bar chart of number of flushes recorded
during each hour of the day. Some women claim that the
timing of taking tamoxifen affects the occurrence of
flushes and so this relationship was explored by plot-
ting the data for tamoxifen and non-tamoxifen users
separately.
The FACT-ES and STAI questionnaires were summed
according to instructions in the relevant handbooks
(Spielberger 1983; Fallowfield et al. 1999). Analysis was
conducted using parametric statistics for these and the
HFNSQ in order to be consistent with published data
(Fallowfield et al. 2004; 2006; Hunter et al. 2004; Schreier
& Williams 2004; Williams & Schreier 2004).
RESULTS
This paper reports data on the patterns of flushing
reported by the women in the study, including incidence,
severity, diurnal patterns, and time since diagnosis or
since menopause. It also reports on the impact of flushes
on the women’s lives, including sleep disruption and
quality of life, and the relationship with state and trait
anxiety.
The age range was 35–77 years (median 55). Further
demographic and treatment details are given in Table 1.
Twenty-eight (18%) women were taking putative rem-
edies for hot flushes, such as herbal supplements (mostly
evening primrose oil or star flower oil) or dietary changes.
As there is no convincing evidence of the efficacy of these
remedies in reducing incidence of hot flushes, they were
not treated as exclusion criteria. They were equally dis-
tributed between the control and treatment groups.
Over a third of the women (51, 34%) in this study had
been diagnosed more than 5 years ago and half (75, 50%)
had undergone their last menstruation more than 5 years
ago (Table 2). There were 35 (23%) women with flushes
who had undergone both menopause and breast cancer
over 5 years ago. In those women taking tamoxifen, most
of the women (38, 95%) had been diagnosed within
5 years. This would be expected as tamoxifen is prescribed
for 5 years.
Number and severity of flushes
The number of flushes experienced by women in this
study was highly variable, ranging from 1 to 30 flushes
per day (3–176) per week, with a median of five flushes
per day (33 per week). Two women recorded over 20
flushes every day for a whole week. Of a maximum score
of 16 for severity per flush, taken from the diaries, the
median score was 5. There was a small, but statistically
Table 1. Demographic and treatment details
Variable Category
Total
sample n (%)
Age group 30–39 2 (1)
40–49 20 (13)
50–59 92 (61)
60–69 33 (22)
70+ 3 (2)
Marital status No current partner 37 (25)
Married 95 (63)
Partner 13 (9)
Missing data 5 (3)
Ethnic origin Afro-Caribbean 2 (1)
Asian 2 (1)
Caucasian 143 (95)
Other (inc. mixed race) 3 (2)
Time since Less than 2 years 53 (35)
Diagnosis 2–5 years 46 (31)
Over 5 years 51 (34)
Time since last
menstruation
Less than one year 18 (12)
1–2 years 23 (15)
2–5 years 34 (23)
More than 5 years 75 (50)
Currently taking Yes 83 (55)
Tamoxifen No 67 (45)
Had chemotherapy Yes 74 (49)
No 76 (51)
Had oophorectomy Yes 16 (11)
No 134 (89)
Taking any other
treatment or
medication
Yes 58 (39)
No 92 (61)
Currently taking Yes 12 (8)
Levothyroxine No 138 (92)
Other remedies for hot
flushes
Yes 28 (19)
No 122 (81)
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significant correlation between the number of flushes
and the severity of flushing (0.24: P < 0.01). There were
no significant correlations between incidence or severity
of flushes recorded and age, marital status, time since
diagnosis or time since menopause. The mean overall
problem rating on the HFNSQ was 4.85 (SD = 2.2) for
daytime flushes and 5.04 (SD = 2.4) for night sweats on a
10-point scale. The component parts of these scores are
given in Table 3.
There were no differences in the number or severity of
flushes with use of tamoxifen or chemotherapy (Table 4).
There was an apparent correlation in the number of
flushes experienced by women who were taking ‘other
medications’. This was a non-specific category to allow
women to list any medications they were taking. On reex-
amining the data, this category included a wide range of
very different medications, such as paracetamol, ibupro-
fen and frusemide, and no individual candidate could be
identified which might have contributed to this phenom-
enon. None of the medications were associated with
flushing, and none were common among the group. The
most frequently noted prescribed medicine was levothy-
roxine, being used by 12 (8%) of the sample, but there was
no difference in flushing between those who were and
who were not using levothyroxine.
Diurnal patterns
Broadly speaking, there was little clear evidence of a
diurnal pattern in flushing. There was a low incidence of
flushes between midnight and 06.00 h. There was then a
rise which continued throughout the whole day until mid-
night. However, there did appear to be a marked peak
between 10.00 and 11.00 h in those women taking tamox-
ifen (see Figs. 1 and 2). Over the course of the whole study,
298 flushes were recorded at this time in women not
taking tamoxifen, and 394 (24% more) flushes in those
who were taking tamoxifen.
Change over time
The number of flushes was monitored in those women
who entered the trial but who did not receive the inter-
vention. In this group, the number of flushes were reduced
in over 3 months from a median of 37 to 31.5 flushes per
week, and from a median severity of 4.7 to 4.2, but these
changes were not significant.
Loss of sleep
Disturbed sleep was recorded by 72% (n = 90) women.
Over the course of the study, 36% of recorded nights were
disrupted, equating to half of the nights of those women
experiencing disrupted sleep. Lost sleep ranged from a few
minutes to 6 h, with a median of 30–44 min. In 38%
(n = 280) of nights that were disrupted, over 1 hour’s sleep
was lost. For those who experienced them, night sweats
appeared to have a greater impact than hot flushes on
everyday life, as they recorded a mean score of 4.27 on the
HFNSQ for this factor (see Table 3).
Relationship between anxiety and flushing
It was proposed that there might be a link between anxiety
and flushing, either in relation to incidence and severity,
or as a predictor of who would respond to relaxation train-
ing. The mean state anxiety at baseline was 37.1 (SD 10.7)
and the mean trait anxiety was 40.2 (SD 9.9), where a
higher number indicates more anxiety (Table 5). This is
similar to norms given by Spielberger (1983) for peri-
menopausal women (Table 5), although high when com-
pared with women of the same age. When comparing
these data with women during treatment for breast
cancer, it appears that both state and trait anxiety are
Table 2. Numbers of women by treatment by time since diagnosis and time since last menstruation
Time since diagnosis (years) Time since last menstruation (years)
Treatment <2 2–5 >5 Total <1 1-2 2–5 >5 Total
Tamoxifen only 22 (15%) 16 (11%) 2 (1%) 40 (27%) 3 (2%) 6 (4%) 9 (6%) 22 (15%) 40 (27%)
Chemotherapy only 7 (5%) 3 (2%) 21 (14%) 31 (21%) 5 (3%) 3 (2%) 3 (2%) 20 (13%) 31 (21%)
Tamoxifen & chemotherapy 20 (13%) 19 (13%) 4 (3%) 43 (29%) 7 (5%) 9 (6%) 14 (9%) 13 (9%) 43 (29%)
Neither tamoxifen nor
chemotherapy
4 (3%) 8 (5%) 24 (16%) 36 (24%) 3 (2%) 5 (3%) 8 (5%) 20 (13%) 36 (24%)
Total 53 (35%) 46 (31%) 51 (34%) 150 (100%) 18 (12%) 23 (15%) 34 (23%) 75 (50%) 150 (100%)
Table 3. Mean HFNSQ problem rating score (score out of 10)
Hot flushes (SD) Night sweats (SD)
Problem 5.8 (2.33) 5.78 (2.48)
Distress 4.86 (2.38) 5.08 (2.53)
Interference to daily life 3.38 (2.55) 4.27 (2.72)
Mean overall problem
rating
4.85 (2.21) 5.04 (2.37)
HFNSQ, Hot Flushes and Night Sweats Questionnaire.
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broadly similar to those on active treatment (Schreier &
Williams 2004).
There was a small, but significant correlation between
the severity of flushing and state anxiety (0.29: P < 0.01),
but not trait anxiety. There was no correlation between
the number of flushes and either state or trait anxiety
(Table 5).
Quality of life
The FACT-ES quality of life scores are given in Table 5
and compared with previous data published by Fallowfield
et al. (1999). The mean quality of life (163.5) was poorer in
this sample than for other women with breast cancer,
including those taking adjuvant tamoxifen or those under-
Table 4. A comparison of number and severity of flushes with different treatments (n = 125)
Treatment
Number of flushes per person
per week median (IQ range) P-value
Severity per flush
median (IQ range) P-value
Tamoxifen
Yes 33.0 (21.0–53.0) 4.4 (3.3–5.9)
No 33.0 (19.0–76.5) 0.99 4.9 (3.3–6.1) 0.66
Chemotherapy
Yes 31.5 (20.0–71.0) 4.4 (3.3–6.0)
No 37.0 (20.0–52.0) 0.71 5.0 (3.7–5.9) 0.35
Oophorectomy
Yes 53.0 (27.0–85.0) 4.9 (2.9–6.0)
No 33.0 (19.3–51.0) 0.16 4.6 (3.3–6.0) 0.61
Other treatment
Yes 34.0 (16.0–72.0) 5.6 (4.3–6.7)
No 33.0 (21.8–52.3) 0.79 4.2 (3.0–5.3) <0.01*
Levothyroxine
Yes 27.0 (18.0–78.0) 5.3 (3.7–6.1)
No 33.5 (20.0–57.0) 0.79 4.5 (3.3–6.0) 0.52
Other remedies for flushes
Yes 50.0 (23.0–85.8) 4.7 (3.6–5.4)
No 31.0 (20.0–47.0) 0.04 4.6 (3.3–6.1) 0.72
*indicates statistical significance.
P-values relate to two-tailed Mann–Whitney test.
Figure 1. Diurnal pattern of incidence
of hot flushes in women not taking
tamoxifen.time of day
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going chemotherapy. In most sub-domains, the quality of
life of this group was broadly similar to other groups,
except for the endocrine subscale, which asks specific
questions about endocrine related symptoms, including
hot flushes, where quality of life was lower.
DISCUSSION
Previous figures published for hot flushes in women
taking tamoxifen for breast cancer showed an average of
20.3 per week and mean problem rating of 4.79 (SD 3.1)
(Hunter et al. 2004). The women in the current study
experienced more flushes and found them more problem-
atic, despite the fact that many of these women had under-
gone menopause many years earlier. Fifty per cent of this
sample had their last menstruation more than 5 years
previously.
There has been an assumption among health care pro-
fessionals that flushes reduce over time and are expected
to stop on cessation of tamoxifen use after 5 years. Data
from this trial indicate that flushes may be much more
long-lasting, causing a problem more than 5 years from
diagnosis in over a third of this sample of women. Half of
the women had undergone their last menstruation more
than 5 years ago. For some women, flushes may have
returned following previous natural menopause due to
cancer treatment, such as tamoxifen. As further evidence
that flushes are long-lasting, no correlations were seen in
the number or severity of flushes with either time since
diagnosis or time since last menstruation, and, without
intervention, no significant reduction was seen in flushes
over 3 months. Hunter et al. (2004) have previously
reported that hot flushes are persistent in women taking
tamoxifen. However, 45% of our sample were no longer
taking tamoxifen and so hot flushes are shown to be a
problem for many women post-breast cancer, not only
those on tamoxifen.
The relative lack of diurnal pattern has been reported
elsewhere (Carpenter et al. 2001). In this trial, there
appeared to be slightly more flushes in the early morning
and late evening, with few occurring at night. It is pos-
sible that in a proportion of cases, flushes occurred at
night during sleep but did not cause women to wake.
This may highlight the limitations of the diary method.
Research, which requires precise measures of occurrence,
may need to use external measures. The use of objective
measurement of hot flushes has been debated and exter-
nal skin conductance has been used to measure hot
flush incidence more reliably (Carpenter et al. 2004).
However, objective measures may not accurately capture
the distress caused to women, and it is recommended
that both objective and subjective measures of flushes
are needed (Miller & Li 2004). In this trial, the impact
on women’s lives was the focus and therefore the
experience as recorded by the women was of more
importance.
The marked peak between 10.00 and 11.00 h in women
taking tamoxifen has not been reported elsewhere. The
Figure 2. Diurnal pattern of incidence of
hot flushes in women taking tamoxifen. time of day
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cause of this is unclear, as no data were gathered as to the
time of day that tamoxifen was taken, although the usual
prescribing pattern was one 20 mg tablet each morning.
Anecdotally, some women claim that splitting the dose of
tamoxifen, taking 10 mg in the morning and 10 mg in the
evening, reduces flushing. One explanation might be that
there is a short-term peak in tamoxifen after taking the
tablet which exacerbates flushing. Women who take
medication at night may then sleep through the peak or
conversely, they may find that they have more disrupted
nights. Further research is required to explain and confirm
this phenomenon.
Although fewer flushes were recorded at night, sleep
disturbance appears to be a major problem, with 72% of
the women in this sample experiencing disturbed sleep
as a consequence of their flushes in half of all the nights
recorded. Although this might only be for a few minutes,
it could also be several disruptions to a night and up to
6 h sleep lost in one night was recorded. The fact that
sleep disruption happened night after night for years was
likely to have a major impact on the lives of these
women.
The relative contributions of different cancer treat-
ments to precipitating menopause can be inferred from
this sample. Where breast cancer and menopause coin-
cided, 14% had chemotherapy only, 23% had tamoxifen
only and 56% had both chemotherapy and tamoxifen.
These figures may be influenced by the treatment patterns
in the hospitals where the sample was taken, as the use of
chemotherapy and tamoxifen together may be much more
frequent than either tamoxifen or chemotherapy alone.
Nevertheless, these findings support evidence provided by
previous authors, such as Biglia et al. (2003), that meno-
pause can be caused by chemotherapy or tamoxifen alone
and is much more likely when chemotherapy and tamox-
ifen are combined. There was no indication in this trial
that the flushes that may have resulted from tamoxifen or
chemotherapy were materially different from normal
menopausal flushes, either in number or severity. This
reinforces previous findings by Gupta et al. (2006). The
median number of flushes for women having had
oophorectomy was much higher (55 per week) than for
other groups (33 per week). However, there were only
three women in this group, which was insufficient for
statistical analysis to be robust.
The fact that trait anxiety is higher in this group of
women than in other women of the same age suggests that
women with a more anxious personality may be more
prone to experience troubling hot flushes. However, this
was not borne out in further analysis as no relationship
was seen between the number and severity of hot flushes
and trait anxiety. There was a correlation between state
anxiety and the severity of flushing, which might indicate
that more severe flushes cause women to be more
anxious. However, there was no clear link between
anxiety and flushing.
The quality of life appeared to be affected in this group,
as scores on the FACT-ES were worse than in other
studies in women with breast cancer (Fallowfield et al.
1999). However, this low level of quality of life was nearly
all accounted for by the scoring on the endocrine subscale,
which suggests that the total quality of life score was
heavily influenced by hot flushes. Differences in quality of
life scores between groups were not great, however, and
standard deviations were high, which suggest that these
findings should be interpreted cautiously. Nevertheless,
there is clearly much distress caused by flushes and night
sweats, potentially causing a major problem in women’s
lives.
The sampling was a limitation in this study, as many
women chose not to be included if they did not find
flushes to be a problem, or if flushes were severe enough
to require proven treatments. As a consequence, data
were only collected from 39% women with flushes who
were approached for the study, representing a mid-range
of severity. There was also a high withdrawal rate from
the study of 30% from initial recruitment, which was
consistent with pilot work (Fenlon 1999). The reasons
given for withdrawal suggest that perhaps women did not
rate hot flushes as very important in comparison with
cancer and cancer treatment. A further limitation of the
study was that data were gathered primarily from Cau-
casian women.
CONCLUSIONS
Despite the fact that data presented here do not represent
women who are either the worst or the least affected by
hot flushes after breast cancer, there is clear evidence that
hot flushes continue to be regarded as a problem for
women long after treatment for breast cancer has been
completed, causing distress, disrupted sleep and interfer-
ence to daily life. There appears to be a morning peak in
flushing in women taking tamoxifen, but there is no evi-
dence that menopausal flushes are worse or more frequent
due to the use of tamoxifen or chemotherapy when com-
pared with normal menopausal flushes. Longitudinal data
about the natural history of flushes after breast cancer is
still lacking, and prospective, observational research is
needed to provide women with accurate information
about hot flushes and to establish a framework for future
interventions.
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